New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
What outcomes are associated with early preventive dental care among Medicaid-enrolled children in Alabama

What outcomes are associated with early preventive dental care among Medicaid-enrolled children in Alabama

Preventive dental care provided by a dentist for children before the age of 2 enrolled in Medicaid in Alabama was associated with more frequent subsequent treatment for tooth decay, more visits and mo
World medicine November 11,2023
What outcomes are associated with early preventive dental care among Medicaid-enrolled children in Alabama

What outcomes are associated with early preventive dental care among Medicaid-enrolled children in Alabama

Preventive dental care provided by a dentist for children before the age of 2 enrolled in Medicaid in Alabama was associated with more frequent subsequent treatment for tooth decay, more visits and mo
World medicine November 11,2023
Team designing new drug for common heart condition

Team designing new drug for common heart condition

An international research team led by medical scientists at the University of Alberta has shown that new medications based on resveratrol—a compound found in red wine and nuts—may be used to treat a c
World medicine November 11,2023
Team designing new drug for common heart condition

Team designing new drug for common heart condition

An international research team led by medical scientists at the University of Alberta has shown that new medications based on resveratrol—a compound found in red wine and nuts—may be used to treat a c
World medicine November 11,2023
3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

Two leading pathology and diagnostics companies, 3DHISTECH of Hungary and Epredia, a member of PHC Group (headquartered in Japan), announce the opening of the Pathology Innovation Incubator in Budapes
World medicine November 11,2023
3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

3DHISTECH and Epredia open pathology innovation incubator to accelerate advancements in cancer diagnostics

Two leading pathology and diagnostics companies, 3DHISTECH of Hungary and Epredia, a member of PHC Group (headquartered in Japan), announce the opening of the Pathology Innovation Incubator in Budapes
World medicine November 11,2023
Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Yi Lin, MD, PhDMinimal residual disease (MRD) negativity sustainedfor 6 months or longer with ciltacabtagene autoleucel (cilta-cel; Carvykti) prolongedduration of response (DOR) and progre
World medicine November 09,2023
Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Yi Lin, MD, PhDMinimal residual disease (MRD) negativity sustainedfor 6 months or longer with ciltacabtagene autoleucel (cilta-cel; Carvykti) prolongedduration of response (DOR) and progre
World medicine November 09,2023
Lamanna Details Evolution of CLL Treatment Following Resistance

Lamanna Details Evolution of CLL Treatment Following Resistance

Nicole Lamanna, MDFollowing progression, sequencing noncovalent vs covalent BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia (CLL) is key, and data support treating patien
World medicine November 09,2023
Lamanna Details Evolution of CLL Treatment Following Resistance

Lamanna Details Evolution of CLL Treatment Following Resistance

Nicole Lamanna, MDFollowing progression, sequencing noncovalent vs covalent BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia (CLL) is key, and data support treating patien
World medicine November 09,2023
STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

Rahul Aggarwal, MDThe six transmembrane epithelial antigen of the prostate 1 (STEAP1) has gained traction as a potential therapeutic target in recent years in multiple cancer types due to its overexpr
World medicine November 09,2023
STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

Rahul Aggarwal, MDThe six transmembrane epithelial antigen of the prostate 1 (STEAP1) has gained traction as a potential therapeutic target in recent years in multiple cancer types due to its overexpr
World medicine November 09,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com